ANNX: Phase 2 showed dose-dependent vision protection; ARCHER II’s 15-month analysis is targeted for Q4 2026
阅读少于1分钟
ARCHER Phase 2 showed dose-dependent reductions in confirmed ≥15-letter BCVA loss, with the strongest result at the EM dose. ARCHER II enrolled 659 patients and targets its 15-month primary analysis in Q4 2026.
Original document: Annexon, Inc. [ANNX] Slides Release — Nov. 3 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr